KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.04 USD
+0.08 (1.34%)
Updated Jun 17, 2024 12:21 PM ET
4-Sell of 5 4
F Value B Growth A Momentum D VGM
Brokerage Reports
0 items in cart
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 361 - 366 ( 366 total )
Company: KALA BIO, Inc.
Industry: Unclassified
Cash Runway into 2019 Plus Imminent Material Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Unclassified
Kala Submits NDA for INVELTYS for Post-Op Pain and Inflammation
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Unclassified
Weakness Due to Future Generic Restasis is a Buying Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Unclassified
Company: KALA BIO, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: KALA BIO, Inc.
Industry: Unclassified
We are initiating coverage of KALA with an OUTPERFORM rating and $46 twelve month price target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L